Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Japanese Male Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design)
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2018
At a glance
- Drugs BI 1015550 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 17 Dec 2018 Planned End Date changed from 12 Sep 2018 to 13 Jun 2019.
- 17 Dec 2018 Planned primary completion date changed from 12 Sep 2018 to 13 Jun 2019.
- 17 Dec 2018 Status changed from suspended to recruiting.